Clinical Trial Update: Combination Study of AZD5069 and Enzalutamide. [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 combination trial of AZD5069 with Enzalutamide in metastatic castration-resistant prostate cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• AZD5069 (CXCR2 inhibitor)
• Enzalutamide (enzalutamide)

Snippet

Sponsor: Institute of Cancer Research, United Kingdom | Conditions: Metastatic Castration Resistant Prostate Cancer | Phase 1, Phase 2 | Status: TERMINATED